
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV showcases a positive outlook due to its compelling advancements in gene therapy, particularly demonstrated by the strong data from ongoing Phase 1/2 studies of AMT-130 for Huntington's disease, which has garnered broad scientific support and a favorable risk-benefit profile. The company's strategic collaboration with Bristol Myers Squibb for cardiovascular disease treatments further enhances its growth potential, particularly as it has navigated regulatory processes without new concerns regarding manufacturing or safety. Additionally, positive reviews from the Data Monitoring Committee for AMT-260 in the GenTLE trial highlight the company's commitment to expanding its innovative pipeline, thus positioning uniQure for substantial market penetration in the future.
Bears say
The analysis indicates a negative outlook on uniQure NV's stock largely due to the company's ongoing developmental challenges, highlighted by a significant delay in the submission timeline for the Biologics License Application (BLA) for AMT-130, now expected beyond the previously guided 1Q26. Additionally, as a clinical-stage company with no revenue-generating products, uniQure has consistently incurred financial losses since inception, raising concerns about its sustainability and financial health. The competitive landscape further exacerbates these issues, as emerging therapies targeting similar indications pose a risk to market penetration and pricing strategies, adding pressure on the anticipated success of uniQure’s gene therapy pipeline.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares